montelukast has been researched along with Mastocytosis* in 3 studies
3 other study(ies) available for montelukast and Mastocytosis
Article | Year |
---|---|
[Severe Mast Cell Activation Syndrome in a 15-year-old patient with an hypermobile Ehlers-Danlos syndrome].
We report the history of a 15-year old patient with a hypermobile Ehlers-Danlos syndrome (hEDS) (his mother, his two brothers and his sister have the same phenotype as him). He suffers mainly from a severe mast cell activation syndrome (MCAS) with an overreaction of the skin to any kind of contact (water of the shower, clothes, bed sheets) but he has also fatigue, headaches, and rash. This impressive rash is exacerbated after the shower and he has the urge to rest («shower's sign»). We describe the MCAS and its easy, fast and very effective medication management, without any significant side effects as well as its frequent association with the hEDS. We finally introduce the original term of «MASED» to this MCAS, associated, linked or entangled to hEDS.. Nous présentons le cas d’un jeune patient âgé de 15 ans atteint d’un syndrome d’Ehlers-Danlos (SED) de type hypermobile (sa mère, ses deux frères et sa soeur présentent le même phénotype que lui). Il présente principalement un syndrome d’activation mastocytaire (SAMA) sévère avec une atteinte démesurée au niveau de la peau exposée au simple contact (avec l’eau, les draps, les vêtements), mais également de la fatigue, des céphalées ainsi que des éruptions qui sont exacerbées après la douche avec l’envie impérieuse de se reposer (le «signe de la douche»). Nous décrivons le SAMA, sa prise en charge médicamenteuse simple, rapide et efficace et dépourvue d’effets secondaires notables ainsi que son association fréquente au SED. Nous introduisons finalement le terme original de «SAMED» à ce SAMA associé, lié ou intriqué au SED. Topics: Acetates; Adolescent; Antioxidants; Ascorbic Acid; Cetirizine; Cyclopropanes; Ehlers-Danlos Syndrome; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Male; Mastocytosis; Quinolines; Ranitidine; Sulfides | 2018 |
Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis.
Topics: Acetates; Adult; Anaphylaxis; Cyclopropanes; Delayed Diagnosis; Drug Therapy, Combination; Epinephrine; Fatigue; Flushing; Histamine Antagonists; Humans; Leukotriene Antagonists; Loratadine; Male; Mastocytosis; Quinolines; Ranitidine; Recurrence; Sulfides | 2014 |
The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis.
The presence of leukotriene D4 receptors in human detrusor myocytes and increased urinary leukotriene E4 in patients with interstitial cystitis and detrusor mastocytosis imply a role for cysteinyl containing leukotrienes as proinflammatory mediators in this disease. We examined the efficacy of the cysteinyl leukotriene 1 receptor antagonist montelukast for treating patients with interstitial cystitis and detrusor mastocytosis.. Ten women in whom interstitial cystitis was diagnosed according to National Institute of Diabetes and Digestive and Kidney Diseases criteria and who also had detrusor mastocytosis with a minimum of 28 mast cells per mm.2 muscle tissue were included in this study. Patients received a single dose of montelukast daily for 3 months. The efficacy of treatment was determined by 24-hour urinary frequency, nocturia and pain using visual analog scales.. After 1 month of montelukast treatment there was a statistically significant decrease in 24-hour urinary frequency, nocturia and pain which persisted during the 3 months of treatment. After 3 months 24-hour urinary frequency had decreased from 17.4 to 12 voidings (p = 0.009), nocturia had decreased from 4.5 to 2.8 (p = 0.019) and pain had decreased from 46.8 to 19.6 mm. on a visual analog scale (p = 0.006). No side effects were observed during treatment.. Montelukast treatment resulted in significant improvement in urinary frequency and pain. Its efficacy for decreasing urinary frequency and pain imply a role of leukotriene receptor antagonists for managing interstitial cystitis but further placebo controlled clinical studies are needed. Topics: Acetates; Aged; Cyclopropanes; Cystitis, Interstitial; Humans; Leukotriene Antagonists; Male; Mastocytosis; Middle Aged; Pilot Projects; Prospective Studies; Quinolines; Sulfides; Urinary Bladder Diseases | 2001 |